Otitis Media - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 86
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O7CCFB55C8EEN
Leaflet:

Download PDF Leaflet

Otitis Media - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Otitis Media - Pipeline Review, H2 2016’, provides an overview of the Otitis Media pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Otitis Media
  • The report reviews pipeline therapeutics for Otitis Media by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Otitis Media therapeutics and enlists all their major and minor projects
  • The report assesses Otitis Media therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Otitis Media
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Otitis Media
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Otitis Media Overview
Therapeutics Development
Pipeline Products for Otitis Media - Overview
Pipeline Products for Otitis Media - Comparative Analysis
Otitis Media - Therapeutics under Development by Companies
Otitis Media - Therapeutics under Investigation by Universities/Institutes
Otitis Media - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Otitis Media - Products under Development by Companies
Otitis Media - Products under Investigation by Universities/Institutes
Otitis Media - Companies Involved in Therapeutics Development
Cellceutix Corporation
ContraFect Corporation
GlaxoSmithKline Plc
Lee's Pharmaceutical Holdings Limited
Madam Therapeutics B.V.
Merck & Co., Inc.
MerLion Pharmaceuticals Pte Ltd
Oticpharma Ltd
Otonomy, Inc.
Yuhan Corporation
Otitis Media - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dexamethasone acetate + piperacillin sodium + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
betahistine dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ciprofloxacin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ciprofloxacin hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2189242A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazufloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCL-1402 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Otitis Media - Dormant Projects
Otitis Media - Product Development Milestones
Featured News & Press Releases
May 20, 2016: Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO
May 16, 2016: Otonomy Announces OTIPRIO Data Presentation and Symposium at Combined Otolaryngology Spring Meetings
Mar 18, 2016: Otonomy Announces Publication of OTIPRIO Phase 3 Clinical Trial Results in JAMA Otolaryngology
Mar 03, 2016: Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
Mar 02, 2016: Otonomy Announces Commercial Availability of OTIPRIO
Dec 11, 2015: Otonomy Announces FDA Approval of OTIPRIO for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
Nov 03, 2015: Otonomy Initiates Open-Label Clinical Trial for OTIPRIO in Pediatric Patients With History of Otitis Media Requiring Tympanostomy Tubes
Sep 24, 2015: Otonomy to Present Results for AuriPro Phase 3 Clinical Trials at 2015 AAO-HNSF Annual Meeting
May 07, 2015: Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
Apr 28, 2015: Otonomy Announces FDA Acceptance of AuriPro New Drug Application
Apr 27, 2015: Otonomy Presents AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference
Apr 21, 2015: Otonomy to Present AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference
Mar 26, 2015: Otonomy Initiates Phase 2 Clinical Trial for AuriPro in Label Expansion Indication
Feb 26, 2015: Otonomy Submits New Drug Application to the FDA for AuriPro
Jul 08, 2014: Otonomy Announces Positive Results from Two Phase 3 Trials of AuriPro in Pediatric Patients Undergoing Ear Tube Placement Surgery
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Otitis Media, H2 2016
Number of Products under Development for Otitis Media - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Otitis Media - Pipeline by Cellceutix Corporation, H2 2016
Otitis Media - Pipeline by ContraFect Corporation, H2 2016
Otitis Media - Pipeline by GlaxoSmithKline Plc, H2 2016
Otitis Media - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
Otitis Media - Pipeline by Madam Therapeutics B.V., H2 2016
Otitis Media - Pipeline by Merck & Co., Inc., H2 2016
Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2016
Otitis Media - Pipeline by Oticpharma Ltd, H2 2016
Otitis Media - Pipeline by Otonomy, Inc., H2 2016
Otitis Media - Pipeline by Yuhan Corporation, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Otitis Media - Dormant Projects, H2 2016

LIST OF FIGURES

Number of Products under Development for Otitis Media, H2 2016
Number of Products under Development for Otitis Media - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Cellceutix Corporation
ContraFect Corporation
GlaxoSmithKline Plc
Lee's Pharmaceutical Holdings Limited
Madam Therapeutics B.V.
Merck & Co., Inc.
MerLion Pharmaceuticals Pte Ltd
Oticpharma Ltd
Otonomy, Inc.
Yuhan Corporation
Skip to top


Otitis Media - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Otitis Media - API Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Otitis Media Global Clinical Trials Review, H1, 2016 US$ 2,125.00 Apr, 2016 · 132 pages
Liver Cirrhosis - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 102 pages

Ask Your Question

Otitis Media - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: